Meeting
2023 ASCO Annual Meeting
Neoadjuvant giredestrant + palbociclib (P) vs. anastrozole (A) + P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+, HER2– eBC): Patient (pt)-reported outcomes (PROs) in the randomized, open-label, international phase II coopERA BC study.
Authors
Yeon Hee Park
Samsung Medical Center, Seoul, South Korea
Yeon Hee Park , Vanesa Quiroga , Peter A. Fasching , Aditya Bardia , Vanesa López-Valverde , Tanja Badovinac Crnjevic , Jutta Steinseifer , Jacob Devine , Sara A. Hurvitz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT04436744
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 591)
DOI
10.1200/JCO.2023.41.16_suppl.591
Abstract #
591
Poster Bd #
421
Abstract Disclosures
Similar Posters
First Author: Peter A. Fasching
Poster
2020 ASCO Virtual Scientific Program
A phase II trial of nivolumab (NIVO) + palbociclib (PAL) + anastrozole (ANA) in postmenopausal women and men with estrogen receptor (ER)+/human epidermal growth factor 2 (HER2)- primary breast cancer (BC): CheckMate 7A8.
First Author: Sara M. Tolaney
Poster
2017 ASCO Annual Meeting
Phase II trial of neoadjuvant (neo) palbociclib (Palbo) plus anastrozole (ana) in endocrine resistant clinical stage 2/3 estrogen receptor positive and HER2 negative (ER+ HER2-) breast cancer (BC).
First Author: Nusayba Ali Bagegni
Poster
2016 ASCO Annual Meeting
Phase II trial of CC-486, a DNA methyltransferase inhibitor, in combination with fulvestrant in postmenopausal women with ER+, HER2- metastatic breast cancer who have progressed on an aromatase inhibitor (AI).
First Author: Mario Campone